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Abstract: Bronchodilators are the cornerstone of severe chronic obstructive pulmonary   disease 
(COPD) treatment to improve airflow, symptoms, exercise tolerance, and   exacerbations. There is 
convincing evidence that regular treatment with long-acting bronchodilators is more effective and 
convenient than treatment with short-acting bronchodilators. Long-acting β-2-agonists include 
the twice-daily drugs formoterol and salmeterol and, more recently, once-daily   indacaterol. 
Studies with head-to-head comparisons of long-acting bronchodilators are scant, but novel data 
from controlled trials with the once-daily β(2)-agonist indacaterol indicate superior bronchodi-
lation and clinical efficacy of indacaterol at recommended doses over twice-daily long-acting 
β(2)-agonists, and at least equipotent bronchodilation compared with once-daily tiotropium. The 
recent therapeutic developments in COPD underscore a shift from short-acting bronchodilators 
with multiple dosings per day to reduced dosing frequency and prolonged duration of action, 
including once-daily treatment, with more consistent effects on various clinical outcomes. This 
review summarizes relevant clinical data for twice-daily β-2-agonists in COPD, and further 
focuses on novel data for once-daily indacaterol, including head-to-head comparison trials.
Keywords: COPD, bronchodilators, salmeterol, indacaterol, formoterol, tiotropium, therapy, 
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Background: long-acting β-agonists  
in the treatment of COPD
Current guidelines recommend long-acting bronchodilators as first-line maintenance 
therapy for moderate, severe, and very severe chronic obstructive pulmonary disease 
(COPD), with a preference for inhaled medications over oral theophyllines.1 Until 
recently, the once-daily anticholinergic tiotropium and the twice-daily β(2)-agonists 
salmeterol and formoterol were the most widely used maintenance medications. Both 
classes of agents have been demonstrated to be effective and hold acceptable safety 
profiles. In December 2009, the first once-daily long-acting β-agonist indacaterol 
was approved by the European Medicines Agency, and indacaterol once daily was 
consequently introduced into the market. The availability of a once-daily inhaled 
β-2-agonist for the maintenance treatment of COPD somehow marks a trend in 
the recent therapeutic developments in COPD, indicating a shift from short-acting 
  bronchodilators with multiple dosings per day to reduced dosing frequency and 
prolonged duration of action, including once-daily treatment. This change has been 
consistently associated with improvements in clinical outcomes of COPD patients. 
Alongside the introduction of new bronchodilators, longer duration of bronchodilation 
showed more consistent improvements in lung function and patient-centered outcomes, International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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including airflow (forced expiratory volume in 1 second 
[FEV1]), hyperinflation, symptom control, dyspnea, quality 
of life, physical activity, and exacerbations.2,3 Recent data 
from large-scale clinical trials may also indicate a beneficial 
effect of long-acting bronchodilators on disease progression4 
and even mortality in subsets of patients.5 Finally, a reduc-
tion of dosing frequency for inhaled therapies will simplify 
the management of COPD, ultimately leading to improved 
patient adherence and compliance,6 contributing to better 
clinical outcomes.7 The aim of this review is to summarize 
relevant data and landmark studies comparing the efficacy 
of short- versus longer-acting bronchodilators in COPD, 
including new data for once-daily indacaterol.
Clinical benefits of twice-daily  
long-acting β-2-agonists in COPD
The long-acting β(2)-agonists (LABA) formoterol and 
  salmeterol were licensed for the treatment of COPD over a 
decade ago. Both drugs have a duration of action of approxi-
mately 12 hours, requiring a twice-daily dosage.8,9   Formoterol 
and salmeterol are more effective than   short-acting broncho-
dilators in improving lung function (FEV1),10–13 with improve-
ments in symptoms for formoterol versus ipratropium,10 but 
no consistent effect on exacerbations versus regular ipratro-
pium for both.10,12,13 In a study by Rennard et al13 salmeterol 
50 microgram (mcg) twice daily was also not superior to 
regular ipratropium in regard to improving symptoms, 
dyspnea, and exercise. To date, there are no conclusive data 
from comparative studies investigating the effects of sal-
meterol and formoterol head to head on relevant long-term 
outcomes in COPD.14 As was already known from asthma 
trials, formoterol has a faster onset of bronchodilator action 
in COPD versus salmeterol.15,16 Due to the lack of any fur-
ther supporting data, current guidelines do not recommend 
any of theses two twice-daily LABAs over the other for the 
maintenance treatment of COPD.
Both formoterol and salmeterol have been extensively 
studied as monotherapy for COPD as control arms in the 
pivotal studies investigating the efficacy of inhaled cor-
ticosteroids/LABA fixed-dose combination.17–20 In these 
studies, LABA monotherapy was associated with numerous 
clinical improvements; however, as no regular short-acting 
bronchodilator comparator was investigated in any of these 
trials, the data do not allow any definite conclusion about 
the comparative efficacy of twice-daily versus short-acting 
β-agonists in COPD. Direct comparisons between twice-
daily LABAs and the once-daily anticholinergic tiotropium 
in patients with COPD have generally been short term, with 
one report of two combined studies of 6 months’ duration.21 
In comparison with salmeterol, tiotropium provided greater 
improvements in lung function and symptoms,21,22 whereas 
there was only a numerical reduction in exacerbations com-
pared with salmeterol. A subsequent 12-week randomized, 
double-blind study versus salmeterol documented superior 
bronchodilation during 12-hour testing.23 Formoterol pro-
vided similar bronchodilation to tiotropium 12 hours after 
inhalation, but the magnitude of effect was higher during 
the first 2 hours post-dose, consistent with a faster onset 
of bronchodilator action for formoterol.24 A 6-month study 
comparing the combination of tiotropium and formoterol 
with single components and placebo reported no differences 
in outcomes of formoterol monotherapy versus tiotropium.25 
In general, the evidence level has not shown clear distinctions 
between twice-daily LABAs and tiotropium on more clini-
cally oriented outcomes. Currently, an ongoing large-scale 
study will directly compare the effect of tiotropium with 
salmeterol on COPD exacerbations.26
Indacaterol: once-daily β-2-agonist 
with 24-hour duration of action
In December 2009, the once-daily LABA indacaterol was 
approved for the maintenance treatment of COPD in the 
  European Union at a recommended dose of 150 mcg once 
daily and a maximum dose of 300 mcg once daily.   Indacaterol 
is a partial β(2)-agonist with high intrinsic efficacy at the 
receptor level. Unlike other partial agonists, it does not exhibit 
antagonistic behaviour in the presence of isoprenaline (“near 
full agonist”).27 Potency and intrinsic efficacy have been 
  demonstrated in various models, including recombinant recep-
tors, guinea pig trachea, isolated human bronchus, and human 
lung slices, with a selectivity ratio for indacaterol of 28 and 
22 against β1 and β3 receptors.27–29 In these studies, a fast onset 
of action and longer duration of action versus formoterol and 
salmeterol were also demonstrated. Although the prolonged 
duration of action of indacaterol versus other lipophilic β(2)-
agonists like salmeterol can potentially be explained by the 
higher affinity of indacaterol to lipid raft domains within 
the membrane,30 its fast onset of action is related to the high 
intrinsic efficacy at the receptor level.31 Pharmacokinetic data 
taken during multiple-dose studies of indacaterol 400 mcg or 
800 mcg once daily for 14 days   demonstrated rapid absorption 
and a mean elimination half life of .30 hours, whereas, in 
a single-dose study, doses between 600 mcg and 2000 mcg 
were rapidly absorbed with maximum serum concentrations 
reached within 15 minutes.32,33 Steady state after inhalation 
was reached within 12 days of once-daily dosing.34International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Clinical data for once-daily 
indacaterol
At the time of writing, several thousands of patients with 
COPD have received indacaterol in various doses for up to 
52 weeks of treatment during the Phase II and III clinical 
program. Early clinical studies suggested that indacaterol 
produces rapid (within 5 minutes) and sustained (for at least 
24 hours) bronchodilation in patients with various degrees 
of airflow obstruction.35,36 Further, a study by Beier et al37 
confirmed that a single dose of indacaterol 300 mcg provided 
a greater effect on airflow obstruction and resting hyperin-
flation (inspiratory capacity) in patients with COPD than 
twice-daily formoterol 12 mcg.37
In the randomized, controlled Phase III COPD trials 
investigating the effects of treatment with 150 mcg or 
300 mcg indacaterol once daily for up to 52 weeks’ duration, 
indacaterol effectively improved numerous clinical outcomes 
over placebo, including trough FEV1, symptom control, 
dyspnea, quality of life, and exacerbations.38–40 However, the 
Phase III studies also incorporated several active compara-
tor drugs, including the twice-daily LABAs formoterol and 
salmeterol and the once-daily anticholinergic tiotropium.
In a 2-week, open-label comparison study of indacaterol 
300 mcg once daily versus salmeterol 50 mcg twice daily, 
trough FEV1 on day 14 for indacaterol was 90 mL higher 
than for salmeterol (P = 0.011). This was also accompanied 
by superior improvements in resting inspiratory capacity 
across a full 24-hour assessment period on day 14, reaching 
statistical significance at most post-dose timepoints.41
Compared with salmeterol 50 mcg twice daily, inda-
caterol 150 mcg once daily was superior in improving trough 
FEV1 after 12 weeks and 26 weeks (differences +60 mL 
and +70 mL, respectively, P , 0.001), quality of life, dysp-
nea, and need for additional rescue medication in a random-
ized, double-blind, comparison study.39 Superior clinical 
efficacy of 150 mcg indacaterol once daily versus salmeterol 
twice daily was also confirmed in a double-blind, 12-week 
comparison study.42
A long-term comparison of indacaterol 300 mcg once 
daily over 52 weeks showed superior effects of indacaterol 
over formoterol 12 mcg twice daily on lung function (trough 
FEV1), dyspnea, and rescue medication usage.43 In a pooled 
analysis, it appeared that 150 mcg indacaterol once daily also 
provided superior benefits on trough FEV1 after 12 weeks of 
treatment versus formoterol 12 mcg twice daily, regardless 
of concomitant use of inhaled corticosteroids.44
During a 26-week randomized comparison trial, inda-
caterol 150 mcg or 300 mcg once daily was compared with 
placebo and open-label tiotropium 18 mcg once daily over 
26 weeks.45 Trough FEV1 at week 12 increased versus   placebo 
by 180 mL with both indacaterol doses and by 140 mL 
with tiotropium (all P , 0.001). At week 12 and week 26, 
there were also significant treatment differences between 
indacaterol at both doses and tiotropium (+40–50 mL favor-
ing indacaterol), when tested for superiority (P , 0.05, all 
comparisons), although the interpretability of these data may 
be complicated by the fact that tiotropium was administered 
open label. Further clinically relevant improvements were 
observed with indacaterol versus placebo for dyspnea and 
health-related quality of life.
However, a fully (third-party) blinded, randomized, 
double-blinded, crossover clinical comparison of the effects 
of indacaterol 150 mcg and 300 mcg once daily versus 
tiotropium 18 mcg once daily or matching placebo proved 
noninferiority for both doses of indacaterol in regard to trough 
FEV1 after 14 days of treatment compared with tiotropium 
18 mcg, with mean trough FEV1 values again favoring 
indacaterol 150 mcg (+50 mL vs tiotropium) and 300 mcg 
(+30 mL vs tiotropium). Although superiority was not proven 
statistically, these data nevertheless altogether indicate that 
indacaterol provides at least equipotent bronchodilation after 
14 days compared with tiotropium.46
Finally, a further blinded comparison of indacaterol 
150 mcg with tiotropium 18 mcg once daily showed com-
parable effects on trough FEV1 after 12 weeks (1.44 L for 
indacaterol vs 1.43 L for tiotropium, P , 0.001 for noninferi-
ority), with additional benefits for indacaterol over tiotropium 
in regard to dyspnea, health-related quality of life, and rescue 
medication use.47
Pooled analyses and subgroups
Pooled analyses, including some of the aforementioned 
clinical trials, were published during the American Thoracic 
Society 2010 annual meeting. These data demonstrated that 
indacaterol 150 mcg or 300 mcg once daily administered 
over 3–6 months provides significant and clinically mean-
ingful improvement of symptoms, health-related quality 
of life, rescue medication use, and exacerbation rates in 
  moderate-to-severe COPD patients.48,49 Further, it was shown 
that longer-term beneficial effects of indacaterol were not 
dependent on age, concomitant inhaled corticosteroid use, 
and baseline bronchodilator reversibility.44,50,51
Safety
Safety studies with indacaterol addressed the occurrence of 
adverse events and serious adverse events,   cardiovascular International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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safety, and known class effects from β-agonists due 
to   systemic absorption of drug, potentially leading to 
  tachycardia, palpitations, changes in electrocardiogram 
parameters (eg, QT prolongation), hypokalemia, increase 
in blood glucose levels, and adverse events like tremor or 
headache.
Phase II studies
Three multiple-dose Phase II trials primarily evaluating 
safety and tolerability of indacaterol have as yet been fully 
published, two in asthma52,53 and one in COPD.54 These 
three trials incorporated a treatment duration of 28 days. 
However, trials used different dosages of indacaterol, and 
indacaterol was delivered in a multiple-dose dry powder 
inhaler, which differs from the currently marketed single-
dose dry powder inhaler device. In studies by Yang et al53 
and Beier et al54  indacaterol at once-daily doses of 400 mcg 
and 800 mcg from single-dose dry powder inhaler was used, 
whereas Chuchalin et al52 evaluated indacaterol at dosages 
of 200 mcg, 400 mcg, or 600 mcg daily.
In all studies, the overall incidence of adverse events was 
similar for active treatment and placebo groups, and there 
was no dose-related increase in the incidence of adverse 
events. The most common adverse event associated with 
indacaterol use was cough, which was reported in 16.9% and 
15.3% of patients in the indacaterol 400 mcg and 800 mcg 
groups, respectively, in the study by Yang et al;53 in 8.1%, 
17.1%, and 10.3% of patients in the indacaterol 600 mcg, 
400 mcg, and 200 mcg groups, respectively, in the study by 
Chuchalin et al;52 and in 14.7% and 28.4% of patients in the 
400 mcg and 800 mcg groups, respectively, in the study by 
Beier et al.54 For the typical class effects of β-agonists, only 
modest effects were observed. Although Yang et al53 reported 
small changes in postdose serum potassium and glucose 
  levels of asthmatic patients exposed to indacaterol 400 mcg 
or 800 mcg, no effect on these parameters was observed in the 
study by Beier et al54 using the same doses in COPD patients. 
In the study by Chuchalin et al52 in asthmatics, no effect of 
once-daily indacaterol 200 mcg, 400 mcg, and 600 mcg on 
potassium and glucose levels was observed. In this study, 
there were also no changes in pulse rate, blood pressure, or 
mean QTc interval after 28 days’ exposure to indacaterol. 
However, there was a small, statistically significant increase 
of the QTc interval (8.9 ms) and pulse rate (4.9 beats 
per   minute) with the 800 mcg dose (n = 59) on day 28 in the 
study by Yang et al53 but these changes were numerically small 
and not clinically significant. Again, none of these effects 
was observed by Beier et al54 in the study using indacaterol 
400 mcg and 800 mcg once daily in COPD patients.
The effect of indacaterol at dosages up to 600 mcg 
once daily over 14 days on QTc values has been studied 
in a   thorough QT study in healthy subjects. All doses of 
  indacaterol had no effect on mean QTc values, and changes 
were within the regulatory safety margin.55 Finally, inhalation 
of supratherapeutic single doses of indacaterol up to 3000 mcg 
in COPD patients revealed only minor systemic effects.56
Phase III trials
In a 12-week trial investigating 150 mcg indacaterol versus 
placebo for 12 weeks,40 the incidence of any adverse event 
was comparable for indacaterol and placebo (indacaterol 
n = 104, 49.3%; placebo n = 96, 46.8%). There were no 
  cardiac safety issues. No patient had a prolongation of the 
QTc interval beyond 500 msec absolute or .60 msec increase 
from baseline, and no increase of pulse rate was observed.
During a further 26-week comparison trial, the frequency 
of adverse events was comparable for indacaterol 150 mcg 
and 300 mcg with open-label tiotropium and placebo. 
  Similarily, the overall proportion of patients with an increase 
in QTcF of 30–60 msec or .60 msec was low and comparable 
with tiotropium and placebo.57
Finally, during the large-scale comparator trial with 
indacaterol 300 mcg and 600 mcg versus formoterol 12 mcg 
twice daily and placebo over 1 year, adverse events and severe 
adverse events occurred in a similar frequency for both 
doses of indacaterol and placebo. Again, the overall propor-
tion of patients with an increase in QTcF of 30–60 msec 
or .60 msec was low and comparable with formoterol and 
placebo. Further, indacaterol at both doses did not affect 
mean serum potassium at week 52, mean QTc values, or 
average pulse rate.43
Chapman et al38 recently reported on the safety of inda-
caterol 150 mcg and 300 mcg once daily versus placebo 
during the 26-week extension phase of the 26-week open-
label tiotropium comparison study, thereby providing data 
over a total duration of 52 weeks. In their analysis, adverse 
events occurred in 76%, 77%, and 68% of subjects receiv-
ing indacaterol 150 µg, 300 µg, and placebo, respectively, 
whereas serious adverse events occurred in 10.4%, 12.3%, 
and 10.5%, respectively. There were no clinically significant 
effects with indacaterol at both doses on QTc interval or 
potassium or glucose levels.
Finally, Worth et al58 specifically reported on the   cardio- 
and cerebrovascular safety of indacaterol 150 mcg and International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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300 mcg once daily versus placebo and comparator drugs 
salmeterol, formoterol, and tiotropium using Antiplatelet 
Trialists’ Collaboration criteria for cardio-/cerebrovascular 
adverse events. Safety data were pooled from three clinical 
trials.39,43,45 The risk of cardio-/cerebrovascular events was not 
significantly increased for indacaterol at both doses versus 
placebo, and the incidence of notable QTc interval changes 
(.60 ms versus baseline) was low with all treatments. In a 
subgroup of patients analyzed by Holter monitoring, there 
was no relevant effect of indacaterol versus placebo on the 
development of arrhythmias. Mortality was numerically 
lower with all active treatments than with placebo, with a 
70% lower relative risk with indacaterol at both doses versus 
placebo (P = 0.054).
In light of the approved recommended dose of 150 mcg 
and a maximal recommended dose of 300 mcg once daily, 
the overall safety data indicate a favorable tolerability profile 
and a broad therapeutic window for indacaterol.
Summary
Bronchodilators are the cornerstone of treatment for all 
COPD severity stages, with a central role in the symptomatic 
management of COPD. They are given on an as-needed basis 
or on a regular basis to prevent or reduce symptoms and 
  exacerbations. The principal inhaled bronchodilator treat-
ments are β(2)-agonists and anticholinergics, used alone or in 
combination. There is broad evidence that regular treatment 
with long-acting bronchodilators is more effective and conve-
nient than treatment with short-acting bronchodilators. New 
data from trials with the novel once-daily β(2)-agonist inda-
caterol indicate superior bronchodilation and clinical efficacy 
over twice-daily LABAs salmeterol and   formoterol and at 
least equipotent bronchodilation as once-daily   tiotropium. 
Therapeutic developments in COPD indicate a change shift 
from short-acting bronchodilators with multiple dosings per 
day to reduced dosing frequency and prolonged duration of 
action, including once-daily treatment.
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